N-ras mutations in human cutaneous melanoma from sun-exposed body sites

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Molecular and Cellular Biology

• Publication date

  1989-07-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1128/mcb.9.7.3114-3116.1989PMID 2674680PMCID PMC362784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of ultraviolet irradiation-induced mutagenesis of the lacI gene in Escherichia coli and in human 293 cells.

  1989cited by this paper
• Genetic Alterations During Colorectal-Tumor Development

  1989cited by this paper
• Detection of a low frequency of activated ras genes in human melanomas using a tumorigenicity assay.

  1988cited by this paper
• Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction

  1988cited by this paper
• Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

  1988cited by this paper
• KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

  1988cited by this paper
• Activation of N-ras induced by ultraviolet irradiation in vitro.

  1988cited by this paper
• Genetic alterations during colorectal-tumor development.

  1988cited by this paper
• The ras gene family and human carcinogenesis.

  1988cited by this paper
• Solar exposure in the etiology of cutaneous melanoma.

  1987cited by this paper
• Multiple activated oncogenes in human tumors.

  1987cited by this paper
• ras genes.

  1987cited by this paper
• Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

  1987cited by this paper
• The specificity of UV-induced mutations at an endogenous locus in mammalian cells.

  1987cited by this paper
• Risk factors for cutaneous malignant melanoma: the Western Canada Melanoma Study.

  1986cited by this paper
• A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides.

  1986cited by this paper
• The causes of malignant melanoma: results from the West Australian Lions Melanoma Research Project.

  1986cited by this paper
• Mutagenic specificity of ultraviolet light.

  1985cited by this paper
• Cutaneous melanoma in relation to intermittent and constant sun exposure—the western canada melanoma study

  1985cited by this paper
• Sunlight and skin cancer.

  1985cited by this paper
• Activation of N-ras in a human melanoma cell line

  1985cited by this paper
• Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

  1984cited by this paper
• Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient.

  1984cited by this paper

• Insight into structural dynamics involved in activation mechanism of full length KRAS wild type and P-loop mutants

  2024cites this paper
• Glycolysis regulator PFKP induces human melanoma cell proliferation and tumor growth

  2023cites this paper
• Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study

  2022cites this paper
• The Emerging Burden of Genetic Instability and Mutation in Melanoma: Role of Molecular Mechanisms

  2022cites this paper
• Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers—An Overview

  2022cites this paper
• Mutations in two neuroblastoma rat sarcoma oncogenes are associated with progression of haematologic malignancies in Nigeria

  2021cites this paper
• Novel insights into the pathogenesis and treatment of NRAS mutant melanoma

  2021cites this paper
• Unraveling the Wide Spectrum of Melanoma Biomarkers

  2021cites this paper
• Addressing Frequently Asked Questions and Dispelling Myths About Melanocytic Nevi in Children.

  2021cites this paper
• Evolution of molecular targets in melanoma treatment.

  2020cites this paper
• Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients

  2020cites this paper
• Current Molecular Markers of Melanoma and Treatment Targets

  2020cites this paper
• Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma

  2020cites this paper
• Diyarbakır bölgesinde malign melanom hastalarının BRAF mutasyonu analizi

  2020cites this paper
• SnapshotDx Quiz: January 2020.

  2020cites this paper
• MiRNA therapeutics based on logic circuits of biological pathways

  2019cites this paper
• THE ROLE OF EPITHELIAL-TO-MESENCHYMAL TRANSITION AND AUTOPHAGY IN ANTITUMORAL RESPONSE OF MELANOMA CELL LINES TO TARGET INHIBITION OF MEK AND mTOR KINASES

  2019cites this paper
• Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes

  2019cites this paper
• Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome

  2019cites this paper
• Sun Exposure and Melanoma, Certainties and Weaknesses of the Present Knowledge

  2018cites this paper
• Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study

  2018cites this paper
• Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas

  2018cites this paper
• 7.08 – Ultraviolet Radiation as a Carcinogen

  2018cites this paper
• MEK inhibitors for the treatment of NRAS mutant melanoma

  2018cites this paper
• MeK inhibitors for the treatment of NRAS mutant melanoma

  2018cites this paper
• From Ras to Rap and Back, a Journey of 35 Years.

  2018cites this paper
• 17 Understanding Melanocyte Transformation – A Work in Progress

  2018cites this paper
• MeK inhibitors for the treatment of NRAS mutant melanoma

  2018cites this paper
• STRUCTURE BASED DRUG DESIGN OF HIGH AFFINITY KRAS INHIBITORS

  2018cites this paper
• Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report

  2018cites this paper
• Osteogenic Melanoma With Desmin Expression

  2017cites this paper
• Pigmented epithelioid melanocytoma (animal‐type melanoma): An institutional experience

  2017cites this paper
• Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients

  2017cites this paper
• The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma

  2017cites this paper
• Energy metabolism in skin cancers: A therapeutic perspective.

  2017cites this paper
• Metastatic Uveal Melanoma—A Review of Current Therapies and Future Directions

  2017cites this paper
• Mechanisms of Drug Resistance in Melanoma.

  2017cites this paper
• Genetic alterations in rare subtypes of melanocytic tumors; towards improved diagnosis and therapy

  2017cites this paper
• Distinct dynamics and interaction patterns in H‐ and K‐Ras oncogenic P‐loop mutants

  2017cites this paper
• Clinical aspects of molecular profiles in metastatic malignant melanoma

  2017cites this paper
• DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA

  2017cites this paper
• Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

  2017cites this paper
• NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand

  2016cites this paper
• Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.

  2016cites this paper
• Unravelling molecular mechanisms underlying therapy resistance in cutaneous melanoma

  2016cites this paper
• Inherited Gene Mutations in Melanoma

  2016cites this paper
• Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies

  2016cites this paper
• Genetics of Melanoma

  2016cites this paper
• Steroid hormone influence on melanomagenesis.

  2015cites this paper
• pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins

  2015cites this paper
• Current State of Animal (Mouse) Modeling in Melanoma Research

  2015cites this paper
• Computational allosteric ligand binding site identification on Ras proteins.

  2015cites this paper
• Molecular Diagnostics and Tumor Mutational Analysis

  2015cites this paper
• NFAT1 CONTRIBUTES TO MELANOMA TUMOR GROWTH AND METASTASIS BY REGULATING IL-8 AND MMP-3

  2015cites this paper
• Estudi de les alteracions genètiques en melanoma cutani mitjançant hibridació in situ fluorescent: valor diagnòstic i pronòstic

  2015cites this paper
• Cross‐species models of human melanoma

  2015cites this paper
• Role of oxidative and energy metabolism in skin aging and UV-B induced carcinogenesis

  2015cites this paper
• Fibroblasts Promote Resistance to BRAF inhibition; The Role of Molecular, Signaling and Metabolic Changes in Melanoma

  2015influential citation
• Targeting drivers of melanoma with synthetic small molecules and phytochemicals.

  2015cites this paper
• Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma

  2015cites this paper
• BRAF, KIT and NRAS mutations and expression of c‐KIT, phosphorylated extracellular signal‐regulated kinase and phosphorylated AKT in Japanese melanoma patients

  2015cites this paper
• Bringing order to disorder : structural and functional analysis for development of strategies to target myc

  2014cites this paper
• Atlas of Genetics and Cytogenetics in Oncology and Haematology

  2014cites this paper
• Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence

  2014cites this paper
• Head and Neck Mucosal Melanoma: A Review

  2014cites this paper
• Genetic alterations and personalized medicine in melanoma: progress and future prospects.

  2014cites this paper
• MITF in melanoma progression, pathology and survival in vivo

  2014cites this paper
• Proteomic techniques for the discovery of biomarkers associated with uveal melanoma and cutaneous melanoma disease progression

  2014cites this paper
• NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.

  2014cites this paper
• Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

  2014cites this paper
• Pathobiological properties of the ubiquitin ligase Nedd4L in melanoma

  2014cites this paper
• Mutationsanalysen im malignen Melanom

  2013cites this paper
• Studies of NVP-BEZ235 in melanoma.

  2013cites this paper
• Melanoma — Epidemiology, Genetics and Risk Factors

  2013cites this paper
• Galectin-3 Enhances the Malignant Melanoma Phenotype by Regulating Autotaxin

  2013cites this paper
• The genetics of melanoma: recent advances.

  2013cites this paper
• Targeting MAPK pathway in melanoma therapy

  2013cites this paper
• Mutation analysis in malignant melanoma

  2013cites this paper
• Chapter 1 Melanoma — Epidemiology , Genetics and Risk Factors

  2013cites this paper
• HIF1α and HIF2α independently activate SRC to promote melanoma invasion and metastasis

  2013cites this paper
• NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.

  2013cites this paper
• The CDKN2A and MAP Kinase Pathways: Molecular Roads to Primary Oral Mucosal Melanoma

  2013cites this paper
• Clinical and epidemiological studies on prognostic and predicitve factors in cutaneous melanoma

  2013cites this paper
• A Discrete-Event Model of Carcinogenesis

  2013cites this paper
• Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

  2013cites this paper
• Melanoma mutagenesis and aberrant cell signaling.

  2013cites this paper
• What are we learning from the cancer genome?

  2012cites this paper
• Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model

  2012cites this paper
• p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.

  2012cites this paper
• Melanoma primário da mucosa oral: estudo imunoistoquímico e molecular da via da MAPK

  2012cites this paper
• Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune.

  2012cites this paper
• Molecular Testing in Melanoma

  2012cites this paper
• Prognostic factors for melanoma progression and metastasis: from Hematoxylin-Eosin to genetics.

  2012cites this paper
• Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma

  2012cites this paper
• Delving into somatic variation in sporadic melanoma

  2012influential citation
• Targeting NRAS in Melanoma

  2012cites this paper
• Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

  2012cites this paper
• Role of the Wnt/PI3-K Pathway in the Regulation of Beta-catenin in Melanoma Progression

  2012cites this paper
• Resolving mechanisms of apoptosis in response to WNT3A in Melanoma

  2012cites this paper
• Targeting NRAS a Priority for Melanoma Research

  2012cites this paper